Membranous Nephropathy Associated with the Relatively Selective Cyclooxygenase-2 Inhibitor, Etodolac, in a Patient with Early Rheumatoid Arthritis

Toshiro Sugimoto; Masahiro Aoyama; Katsuhisa Kikuchi; Masayoshi Sakaguchi; Naoko Deji; Takashi Uzu; Yoshihiko Nishio; Atsunori Kashiwagi

doi:10.2169/internalmedicine.46.0094

CASE REPORTS

Membranous Nephropathy Associated with the Relatively Selective Cyclooxygenase-2 Inhibitor, Etodolac, in a Patient with Early Rheumatoid Arthritis

Toshiro Sugimoto, Masahiro Aoyama, Katsuhisa Kikuchi, Masayoshi Sakaguchi, Naoko Deji, Takashi Uzu, Yoshihiko Nishio, Atsunori Kashiwagi

Author information

Keywords: membranous nephropathy, rheumatoid arthritis, selective cyclooxygenase-2 inhibitor

JOURNAL OPEN ACCESS

2007 Volume 46 Issue 13 Pages 1055-1058

DOI https://doi.org/10.2169/internalmedicine.46.0094

Details

Abstract

Renal dysfunction and urinary abnormalities, which are usually related to drug toxicity, secondary amyloidosis, or those which overlap with other autoimmune conditions, are frequently observed in patients with rheumatoid arthritis. This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac. The present case suggests that any kind of non-steroidal anti-inflammatory drug can cause membranous nephropathy; thus, physicians should be aware of this renal toxicity when prescribing these drugs.

Corresponding author

Register with J-STAGE for free!